| Symbol | XVIPY |
|---|---|
| Name | XVIVO PERFUSION AB |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 400 Sweden PO Box 53015 |
| Telephone | +46 31 788 21 50 |
| Fax | — |
| — | |
| Website | http://www.xvivoperfusion.com/ |
| Incorporation | SE |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Nasdaq OMX Nordic Exchange Stockholm |
| CIK | 0001898393 |
| Description | XVIVO is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. Our mission is to increase the survival rates of patients awaiting transplantation by providing more effective, clinically proven innovative products that both increase the availability of acceptable donors organs and improve survival after transplantation. We are committed to provide our customers with solutions and systems that can improve the transplant process outcome, facilitate the work for the transplant team, and enhance the long-term outcomes and quality of life of the transplant recipient. Additional info from OTC: |
No news found.